Introduction: When Sound Plans Derail
In the world of medical device development, failure rarely looks like chaos. It often looks like order.
Roadmaps are Gantt-charted. Technical milestones are well-defined. Regulatory pathways are mapped. Teams are talented, clinical insight is strong, and the product vision is clear.
And yet—despite all this structure and logic—the company stalls. Progress halts. Burnout begins. Not because the product doesn’t work.
But because the plan wasn’t built around the capital journey.
This isn’t just a startup problem. We’ve seen it in corporate ventures, university spinouts, and even mid-market MedTech firms pursuing new lines of innovation.
Cash Is the Constraint – Not Technology
In almost every case, the true limiter isn’t technical capability or clinical ambition. It’s cash.
Cash determines:
- How many engineers can be hired
- How many prototypes can be built
- How far you can take validation
- How long the team has before confidence cracks
And yet too many development plans are structured as if funding is a constant, not a constraint.
The Classic Misalignment
Here’s what happens all too often:
- R&D lays out a logical, phased development programme
- Each phase makes technical and clinical sense
- But the burn profile is based on ideal conditions, not capital reality
Result: The company runs out of money just before critical proof is generated. Not because the product failed, but because the budget ran dry before it could be proven.
In regulated healthcare, the timeline between prototype and proof is long. That means every phase must serve a dual purpose: product progress and fundraising ammunition.
Reverse Engineer Your Roadmap From Capital Milestones
Every phase of development should be built around one question:
What evidence does the next funder or budget-holder need to see to commit?
That means mapping:
- What grant bodies need to see for early non-dilutive funding
- What seed investors view as the key de-risking milestones
- What Series A investors expect on clinical, regulatory, and reimbursement fronts
- What internal budget holders need to greenlight additional resourcing
This isn’t about dumbing down development. It’s about sequencing it around survivability.
Case Study: Genomtec ID
Maddison worked with Genomtec to rapidly iterate a field-deployable molecular diagnostics platform. Rather than overbuilding, the team developed a compact, testable, clinically intuitive prototype that achieved single-handed operation in PPE environments. That clarity and speed helped unlock commercial traction and downstream capital, including international licensing interest.
Discipline Is the Differentiator
Once investor requirements are understood, discipline becomes the difference between progress and drift.
That means:
- Delaying features that don’t drive funding
- Defining “good enough” V&V for current stage goals
- Cutting back speculative R&D until capital is secured
This kind of rigour isn’t easy. But strategy is what you choose not to do.
Case Study: OvuSense – Designing to De-Risk
In supporting OvuSense’s early development, Maddison helped the team build ergonomic, manufacturable prototypes that delivered clinical-grade tracking without overinvesting in high-volume manufacturing too early. The team used each version to validate comfort, usability and clinical relevance—de-risking commercial and clinical milestones before raising further capital.
Final Word: Capital-Aligned Product Development Isn’t Optional
It doesn’t matter how smart your engineers are if you run out of cash before they deliver.
Whether you’re a spin-out, a business unit launching a new diagnostic platform, or a growth-stage MedTech company planning your next milestone—the same rule applies:
Development must follow funding. Not the other way around.
If your roadmap isn’t built around capital requirements, it isn’t a roadmap. It’s a risk profile.
Want to build a product plan that keeps you alive long enough to matter?
Let’s talk.
Rob Butterfield
Managing Director
rob.butterfield@maddison.co.uk